Effect of GLP-1 Receptor Agonist, Exenatide on Glucosuria Induced Elevation in ENDOGENOUS GLUCOSE PRODUCTION (EGP)
| Status: | Recruiting |
|---|---|
| Conditions: | Diabetes, Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 2/9/2019 |
| Start Date: | December 15, 2017 |
| End Date: | March 31, 2021 |
| Contact: | Eugenio Cersosimo, MD, PhD |
| Email: | cersosimo@uthscsa.edu |
| Phone: | 210-358-7200 |
In this study, the researchers hope to learn about SGLT2 inhibition on EGP (endogenous
glucose production) and plasma glucose concentration in diabetic subjects. Researchers will
examine diabetes and the role of increased plasma glucagon, decline in plasma insulin, and
fall in plasma glucose concentration.
glucose production) and plasma glucose concentration in diabetic subjects. Researchers will
examine diabetes and the role of increased plasma glucagon, decline in plasma insulin, and
fall in plasma glucose concentration.
This study will examine whether the coadministration of exenatide plus dapagliflozin will
prevent the increase in EGP and result in an additive or even synergistic decrease in plasma
glucose concentration compared to each agent alone.
prevent the increase in EGP and result in an additive or even synergistic decrease in plasma
glucose concentration compared to each agent alone.
Inclusion Criteria:
- BMI = 25-35 kg/m^2
- must be drug naïve and/or on a stable dose (more than 3 months) of metformin and/or
sulfonylurea
- HbA1c >7.0% and <10.0%
- Other than diabetes, subjects must be in good general health as determined by physical
exam, medical history, blood chemistries, CBC, TSH, T4, EKG and urinanalysis.
- Only subjects whose body weight has been stable (± 3 lbs) over the preceding three
months and who do not participate in an excessively heavy exercise program will be
included.
Exclusion Criteria:
- Subjects taking drugs known to affect glucose metabolism (other than metformin and
sulfonylurea) will be excluded
- Individuals with evidence of proliferative diabetic retinopathy, plasma creatinine
>1.4 females or >1.5 males, or 24-hour urine albumin excretion > 300 mg will be
excluded.
We found this trial at
1
site
San Antonio, Texas 78229
Principal Investigator: Eugenio Cersosimo, MD, PhD
Phone: 210-358-7200
Click here to add this to my saved trials
